IP Library › Patent Application 11008091
Patent Application
App. No. 11/008,091

Tumor necrosis factor super family agonists

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/008,091
Abstract

The invention relates to novel proteins with TNFSF agonist activity and nucleic acids encoding these proteins. The invention further relates to the use of the novel proteins in the treatment of TNFSF-related disorders.

Claims (30)

1 . A variant human TNF-α protein comprising the amino acid substitution F144N.

2 . A variant human BAFF protein comprising a sequence having the formula:

Fx(134-158)-Vx(159)-Fx(160-161)-Vx(162)-Vx(163)-Fx(164-204)-Vx(205)-Vx(206)-Vx(207)-Fx(208-210)-Vx(211)-Fx(212-232)-Vx(233)-Fx(234-237)-Vx(238)-Fx(239)-Vx(240)-Fx(241)-Vx(242)-Fx(243-265)-Vx(266)-Vx(267)-Fx(268-272)-Vx(273)-Fx(274-end)

wherein

Fx(134-158) comprises the human wild-type sequence at positions 134-158;

Vx(159) is an amino acid selected from the group consisting of Q, R and K;

Fx(160-161) comprises the human wild-type sequence at positions 160-161;

Vx(162) is an amino acid selected from the group consisting of S, D, L and N;

Vx(163) is an amino acid selected from the group consisting of Y, A, F, H, I, L, T and D;

Fx(164-204) comprises the human wild-type sequence at positions 164-204;

Vx(205) is an amino acid selected from the group consisting of T and I;

Vx(206) is an amino acid selected from the group consisting of Y and F;

Vx(207) is an amino acid selected from the group consisting of A and T;

Fx(208-210) comprises the human wild-type sequence at positions 208-232;

Vx(211) is an amino acid selected from the group consisting of L, E and V;

Fx(212-232) comprises the human wild-type sequence at positions 212-232;

Vx(233) is an amino acid selected from the group consisting of I and V;

Fx(234-237) comprises the human wild-type sequence at positions 234-237;

Vx(238) is an amino acid selected from the group consisting of E, K and Q;

Fx(239) comprises the human wild-type sequence at position 239;

Vx(240) is an amino acid selected from the group consisting of L, F, N, R, Y and Q;

Fx(241) comprises the human wild-type sequence at position 241;

Vx(242) is an amino acid selected from the group consisting of N, A and Y;

Fx(243-265) comprises the human wild-type sequence at positions 243-265;

Vx(266) is an amino acid selected from the group consisting of E, I, K, T, L and R;

Vx(267) is an amino acid selected from the group consisting of N and R;

Fx(268-272) comprises the human wild-type sequence at positions 268-272;

Vx(273) is an amino acid selected from the group consisting of D, A, E, H, N and R;

Fx(274-end) comprises the human wild-type sequence at positions 274 to end;

wherein said variant human BAFF protein has increased agonist activity as compared to human BAFF.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2005
From: EIVAZI, ARAZ; DESJARLAIS, JOHN R.; NGUYEN, DUC-HANH THI; ZALEVSKY, JOHATHAN
To: XENCOR, INC.
Reel/Frame 016671/0488 →